Joseph F Fowler1,2,3,4, James Q Del Rosso1,2,3,4, Refika I Pakunlu1,2,3,4, Srinivas Sidgiddi1,2,3,4. 1. Dr. Fowler is Co-Founder of Dermatology Specialists Research in Louisville, Kentucky, and Clinical Professor of Dermatology, University of Louisville School of Medicine, Louisville, Kentucky. 2. Dr. Del Rosso is Research Director at JDR Dermatology Research in Las Vegas, Nevada; Adjunct Clinical Professor of Dermatology at Touro University Nevada, Las Vegas; and with Dermatology and Cutaneous Surgery at Thomas Dermatology in Las Vegas, Nevada. 3. Dr. Pakunlu is Associate Director of Chemistry, Manufacturing, and Controls. 4. Dr. Sidgiddi is Director of Clinical Development at Promius Pharma, a subsidiary of Dr. Reddy's Laboratories, in Princeton, New Jersey.
Abstract
Objective: To assess patient-reported satisfaction, efficacy, and tolerability associated with the use of betamethasone dipropionate spray 0.05% when applied twice daily in subjects with moderate plaque psoriasis. Design: This was an open-label, multicenter study involving 45 patients with moderate plaque psoriasis, with the aim of evaluating patient-reported outcomes with betamethasone dipropionate spray 0.05%. Patients treated all affected areas twice daily with betamethasone dipropionate (BD) spray 0.05% for 28 days per label instructions. Measurements: Outcome measures included the Treatment Satisfaction Questionnaire for Medication (TSQM), Dermatology Life Quality Index (DLQI), Investigators Global Assessment (IGA), and Total Sign Score (TSS). In addition, the lesions were photographed at baseline (Day 1) and on Day 8, Day 14, and Day 29. Results: The results indicated that BD spray 0.05% treatment is associated with improved quality of life. BD spray 0.05% also led to improved IGA and TSS values and a reduction in the percentage of body surface area affected. Conclusion: In subjects with moderate plaque psoriasis, BD spray 0.05% demonstrated good levels of patient satisfaction and quality of life measures, in combination with improvements in the global assessment of disease and the level of itching experienced by subjects.
Objective: To assess patient-reported satisfaction, efficacy, and tolerability associated with the use of betamethasone dipropionate spray 0.05% when applied twice daily in subjects with moderate plaque psoriasis. Design: This was an open-label, multicenter study involving 45 patients with moderate plaque psoriasis, with the aim of evaluating patient-reported outcomes with betamethasone dipropionate spray 0.05%. Patients treated all affected areas twice daily with betamethasone dipropionate (BD) spray 0.05% for 28 days per label instructions. Measurements: Outcome measures included the Treatment Satisfaction Questionnaire for Medication (TSQM), Dermatology Life Quality Index (DLQI), Investigators Global Assessment (IGA), and Total Sign Score (TSS). In addition, the lesions were photographed at baseline (Day 1) and on Day 8, Day 14, and Day 29. Results: The results indicated that BD spray 0.05% treatment is associated with improved quality of life. BD spray 0.05% also led to improved IGA and TSS values and a reduction in the percentage of body surface area affected. Conclusion: In subjects with moderate plaque psoriasis, BD spray 0.05% demonstrated good levels of patient satisfaction and quality of life measures, in combination with improvements in the global assessment of disease and the level of itching experienced by subjects.
Entities:
Keywords:
Betamethasone dipropionate; Dermatology Life Quality Index; Investigators Global Assessment; Total Sign Score; Treatment Satisfaction Questionnaire for Medication; patient satisfaction
Authors: Alan Menter; Neil J Korman; Craig A Elmets; Steven R Feldman; Joel M Gelfand; Kenneth B Gordon; Alice Gottlieb; John Y M Koo; Mark Lebwohl; Craig L Leonardi; Henry W Lim; Abby S Van Voorhees; Karl R Beutner; Caitriona Ryan; Reva Bhushan Journal: J Am Acad Dermatol Date: 2011-02-08 Impact factor: 11.527
Authors: Roland Aschoff; Anthony Bewley; Annunziata Dattola; Clara De Simone; Mourad Lahfa; Mar Llamas-Velasco; Antonio Martorell; Mira Pavlovic; Michael Sticherling Journal: Dermatol Ther (Heidelb) Date: 2021-09-12